Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
The Federal Reserve Announces Reform Plan for Stress Testing of Large U.S. Banks, Plans to Delay Effective Date of Capital Buffer Requirements

The Federal Reserve Announces Reform Plan for Stress Testing of Large U.S. Banks, Plans to Delay Effective Date of Capital Buffer Requirements

金色财经金色财经2025/04/17 23:03
Show original

The Federal Reserve is refining its reform plan for stress testing of large banks and has submitted a proposal to solicit public comments. The proposal will calculate an average result over two years. The Federal Reserve states it intends to postpone the effective date of the annual stress capital buffer requirement from October 1st to January 1st of the following year, giving banks more time to adapt to the new capital requirements. The proposal will also "make targeted changes to simplify the data collection process related to Board stress tests." The Federal Reserve states that these planned reforms are not aimed at having a material impact on capital requirements.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"Orders remain as expected, but confidence has been re-evaluated." Bank of America: ASML three giants’ cooperation strengthens the long-term High-NA roadmap.

On Tuesday, ASML (ASML.US) became the focus of the market as Bank of America praised the company's additional chip manufacturing equipment supply agreements with TSMC (TSM.US), Intel (INTC.US), and Samsung.

智通财经2026/09/09 08:11
"Orders remain as expected, but confidence has been re-evaluated." Bank of America: ASML three giants’ cooperation strengthens the long-term High-NA roadmap.

Novartis (NVS.US) cardiovascular therapy trial "misfire" drags down Amgen (AMGN.US): stock price plunges to a ten-year low, BMO swiftly downgrades rating

Amgen's stock posted its biggest single-day decline since 2016 on Tuesday, after Novartis announced that a heart disease therapy jointly developed with Ionis Pharmaceuticals suffered a setback in late-stage clinical trials. Meanwhile, BMO downgraded the pharmaceutical giant's rating from "Outperform" to "Market Perform," citing the failure of its candidate drug pelacarsen to meet expectations in its phase III clinical trial.

智通财经2026/09/09 08:11
Novartis (NVS.US) cardiovascular therapy trial "misfire" drags down Amgen (AMGN.US): stock price plunges to a ten-year low, BMO swiftly downgrades rating

NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions

Rothe Development, a contractor that provides engineering and mission operations services to NASA and other federal agencies, filed on Tuesday with the SEC to raise up to $50 million through an initial public offering (IPO).

智通财经2026/09/09 08:11
NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions